8.2 Recognition and Treatment of Adverse Reactions & Clinical Complications

8.2 Recognition and Treatment of Adverse Reactions & Clinical Complications

[!NOTE] ANCC Blueprint Focus: Cardiovascular nurses must rapidly identify acute drug toxicities, differentiating idiosyncratic hypersensitivity from predictable pharmacodynamic toxicities. Mastery of emergency antidotes (Digoxin Immune Fab), specialized volume resuscitation targets (rhabdomyolysis nephroprotection), non-allergic airway rescue (bradykinin angioedema), and electrical/pharmacological stabilization of polymorphic ventricular tachycardia is essential for Domain III (Evaluation and Modification).

Rapid clinical recognition and emergency intervention are vital when patients experience life-threatening adverse drug reactions or acute toxicities from cardiovascular pharmacotherapy. Delays in identifying toxic signatures can lead to irreversible end-organ damage or cardiac arrest.

---

Digoxin Toxicity: Manifestations, Triggers & DigiFab Protocols

Despite declining use as a first-line agent, digoxin remains clinically valuable in select patients with Heart Failure with reduced Ejection Fraction (HFrEF) and for ventricular rate control in atrial fibrillation with coexisting heart failure. However, its therapeutic margin is exceptionally narrow.

1. Therapeutic Windows & Pathophysiology

• Target Serum Concentrations: Contemporary heart failure guidelines mandate a target serum digoxin trough concentration of 0.5 to 0.9 ng/mL. Serum concentrations ≥ 1.0 to 1.2 ng/mL are associated with increased all-cause mortality, particularly in women and the elderly. Overt clinical toxicity frequently occurs at levels > 2.0 ng/mL, but can manifest at 'therapeutic' levels (1.0 to 1.5 ng/mL) in the presence of sensitizing electrolyte derangements.
• Electrolyte Sensitivities:
  • Hypokalemia: Extracellular potassium competes with digoxin for the external binding site on the myocardial sarcolemmal $Na^+/K^+$ ATPase pump. In hypokalemia, decreased potassium competition allows increased digoxin binding, maximizing pump inhibition and intracellular calcium overload.
  • Hypomagnesemia: Magnesium is an essential cofactor for the $Na^+/K^+$ ATPase pump. Low magnesium impairs enzyme function, directly magnifying digitalis cardiotoxicity.
  • Hypercalcemia: Digoxin enhances sarcoplasmic calcium accumulation; hypercalcemia synergistically accelerates calcium overload, dramatically increasing the risk of fatal ventricular fibrillation.

2. Clinical Triad of Toxicity

• Gastrointestinal (Earliest Warning Signs): Anorexia, nausea, vomiting, persistent abdominal discomfort, and diarrhea. Often misattributed to viral gastroenteritis or heart failure cachexia.
• Neurological & Ocular Disturbances: Fatigue, lethargy, confusion, delirium, headache, blurred vision, photophobia, and altered color perception—classically xanthopsia (yellow-green halos around lights and illuminated objects) or scotomas.
• Cardiovascular Arrhythmias: The hallmark electrophysiological mechanism is increased automaticity combined with depressed AV nodal conduction:
  • Frequent Premature Ventricular Contractions (PVCs): Particularly ventricular bigeminy or trigeminy (most frequent initial dysrhythmia).
  • Bidirectional Ventricular Tachycardia: Wide-complex ventricular tachycardia characterized by a beat-to-beat alternating axis in the frontal plane. This arrhythmia is virtually pathognomonic for digitalis toxicity.
  • Paroxysmal Atrial Tachycardia with AV Block (PAT with block): Accelerated atrial rate (150–200 bpm) caused by increased atrial automaticity coupled with 2:1 or variable AV block due to direct vagomimetic AV nodal depression.
  • Conduction Blocks & Bradyarrhythmias: Accelerated junctional rhythm, marked sinus bradycardia, second-degree (Mobitz I), or third-degree complete AV block.

                                ┌──> GI: Anorexia, Nausea, Vomiting (Earliest Warning)
                                │
Clinical Triad of               ├──> Neuro/Visual: Xanthopsia (Yellow-Green Halos), Confusion, Scotomas
Digoxin Toxicity                │
                                └──> Arrhythmias: Ventricular Bigeminy, Bidirectional VT,
                                                  PAT with Block, High-Degree AV Block

3. Emergency Treatment & Digoxin Immune Fab (DigiFab)

• Initial Nursing Actions: Immediately discontinue digoxin and potassium-wasting diuretics. Place on continuous 12-lead ECG telemetry. Draw STAT serum digoxin level, serum electrolytes (potassium, magnesium), BUN, and serum creatinine.
• Electrolyte Management: Replete potassium to high-normal (4.0 to 5.0 mEq/L) and magnesium to > 2.0 mg/dL. Critical Exception: In acute massive oral overdose, digoxin poisons skeletal muscle $Na^+/K^+$ pumps, preventing potassium influx and triggering severe hyperkalemia. If serum potassium is > 5.0 mEq/L in acute overdose, DO NOT administer potassium.
• Avoid Intravenous Calcium: Administration of IV calcium salts (calcium chloride or gluconate) in digitalis toxicity can trigger intractable tetanic myocardial contraction ('stone heart') and fatal asystole.
• Specific Antidote: Digoxin Immune Fab (DigiFab / Digibind):
  • Indications: Severe, life-threatening ventricular arrhythmias (sustained VT, VF, bidirectional VT); symptomatic bradyarrhythmias or high-degree AV blocks unresponsive to atropine; acute ingestion of > 10 mg in adults (> 4 mg in children); or serum potassium > 5.0 mEq/L in the setting of acute digitalis toxicity.
  • Dosing Formula: Number of vials = $[(\text{Serum Digoxin in ng/mL}) \times (\text{Weight in kg})] / 100$. If the ingested dose is known: Number of vials = Ingested dose (in mg) $\times 0.8 / 0.5$. In cardiac arrest or imminent collapse when serum levels are unknown, administer 10 to 20 vials IV push empirically.
  • Post-Administration Laboratory Warning: DigiFab binds free digoxin molecules to form Fab-digoxin complexes that are cleared by the kidneys. Standard commercial digoxin assays measure total (free plus bound) digoxin. After DigiFab administration, total serum digoxin levels rise up to 10- to 20-fold due to circulating complexes, while free active digoxin drops to zero. Serum digoxin levels are completely uninterpretable and should not be drawn for 1 to 2 weeks post-DigiFab.

---

Statin-Induced Rhabdomyolysis & Immune-Mediated Necrotizing Myopathy

Statin therapy is foundational in cardiovascular prevention, yet statin-associated muscle symptoms (SAMS) range from benign myalgia to lethal skeletal muscle necrosis.

Emergency Management of Acute Rhabdomyolysis

1. Aggressive Intravenous Hydration: The cornerstone of nephroprotection. Initiate isotonic crystalloid (0.9% Normal Saline or balanced crystalloid) at 200 to 300 mL/hr, titrated to maintain a vigorous urine output of 200 to 300 mL/hr (or 2 to 3 mL/kg/hr). Rapid fluid expansion flushes filtered myoglobin from renal tubules, dilutes intratubular cast-forming proteins, and combats renal vasoconstriction.
2. Urinary Monitoring: Insert an indwelling urinary catheter with an hourly urometer. On urinalysis, the urine dipstick will test strongly positive for 'blood / hemoglobin' because the reagent strip cross-reacts with the heme moiety of myoglobin; microscopic examination reveals an absence of intact red blood cells, confirming myoglobinuria.
3. Urine Alkalinization: In acidic urine ($pH < 5.6$), myoglobin dissociates into ferrihemate (hematin), which causes direct proximal tubular cytotoxicity and lipid peroxidation. An intravenous sodium bicarbonate infusion (e.g., 150 mEq in 1 L D5W) may be titrated to achieve a urine pH > 6.5, provided systemic alkalosis ($pH > 7.50$) and severe hypocalcemia are avoided.
4. Electrolyte Surveillance: Monitor serial potassium, phosphate, and calcium levels every 4 to 6 hours. Manage acute hyperkalemia aggressively (calcium gluconate for cardiac membrane stabilization, insulin with dextrose, sodium zirconium cyclosilicate, or emergent renal replacement therapy for refractory hyperkalemia or anuric renal failure).

---

ACE Inhibitor-Induced Angioedema: Non-Allergic Airway Crisis

Angioedema occurs in 0.1% to 0.7% of patients receiving Angiotensin-Converting Enzyme (ACE) inhibitors. It accounts for nearly 40% of all drug-induced angioedema presentations in emergency departments.

1. Mechanism: Bradykinin vs. Histamine

• Biochemical Pathway: ACE (also known as kininase II) is the primary physiological enzyme responsible for degrading bradykinin and substance P into inactive peptide fragments. Inhibition of ACE leads to the unhindered tissue accumulation of bradykinin.
• Vascular Effect: Bradykinin binds to endothelial $B_2$ receptors, activating nitric oxide and prostacyclin release, causing profound localized arteriolar vasodilation and increased venular endothelial permeability, resulting in rapid extravasation of fluid into the submucosal and subcutaneous spaces.
• Distinct Clinical Features: Unlike IgE-mediated anaphylaxis, bradykinin-induced angioedema lacks urticaria, hives, and pruritus. Furthermore, it can occur at any time—while 50% of cases manifest within the first 1 to 4 weeks of starting therapy, up to 30% occur unpredictably after months or years of uneventful therapy.

2. Clinical Presentation & Emergency Airway Management

• Anatomical Distribution: Rapidly progressive, non-pitting, asymmetrical swelling of the lips, tongue, floor of the mouth, uvula, soft palate, and larynx. In severe cases, the tongue protrudes from the mouth, causing upper airway obstruction, hoarseness, stridor, and asphyxiation.
• Priority Action: Airway Assessment: Inspect the posterior pharynx and vocal cords immediately via bedside nasopharyngoscopy. If there is involvement of the tongue base, uvula, or larynx, or if the patient exhibits hoarseness or inspiratory stridor, execute early endotracheal intubation before complete anatomical distortion renders oral and nasal intubation impossible. Prepare for emergency bedside surgical cricothyroidotomy.

3. Resistance to Standard Anaphylaxis Therapies & Targeted Reversal

• Standard Medical Therapies Ineffective: Because this reaction is entirely non-histaminergic and non-allergic, epinephrine, H1/H2 antihistamines (diphenhydramine, famotidine), and systemic corticosteroids (methylprednisolone) have little to no proven efficacy. While often administered empirically on arrival before the diagnosis is clarified, they must never provide false reassurance or delay emergency airway control.
• Targeted Pharmacotherapy:
  • Icatibant (Firazyr): A synthetic selective competitive bradykinin $B_2$ receptor antagonist. Administered as a single subcutaneous injection of 30 mg into the abdominal wall; produces rapid regression of tissue swelling.
  • Fresh Frozen Plasma (FFP): Contains endogenous plasma kininase II (ACE). Infusion of 2 units of FFP provides active enzyme that rapidly breaks down circulating bradykinin, serving as an effective rescue therapy when icatibant is unavailable.
  • C1-Esterase Inhibitor Concentrate: Replaces regulatory protein to halt kallikrein-kinin activation.
• Definitive Clinical Mandate: Permanently discontinue the ACE inhibitor. Angiotensin Receptor Blockers (ARBs) are generally contraindicated or used only with extreme caution, as cross-reactivity has been documented in up to 2% to 8% of patients. Document a severe, permanent allergy in the patient's medical record.

---

Antiarrhythmic-Induced Proarrhythmia: QT Prolongation & Torsades de Pointes

Proarrhythmia—the paradoxical induction or aggravation of a cardiac arrhythmia by an antiarrhythmic drug—is a feared complication of electrophysiological pharmacotherapy.

1. Cellular Mechanism of Torsades de Pointes (TdP)

• $I_{Kr}$ Channel Blockade: Class IA (quinidine, procainamide, disopyramide) and Class III antiarrhythmic drugs (sotalol, dofetilide, ibutilide, amiodarone, dronedarone) inhibit the rapid component of the delayed rectifier potassium current ($I_{Kr}$). This slows Phase 3 repolarization of the ventricular action potential, prolonging ventricular refractoriness and manifesting on the surface 12-lead ECG as QT interval prolongation.
• Early Afterdepolarizations (EADs): Prolonged plateau repolarization allows reactivation of L-type calcium channels and the forward mode of the $Na^+/Ca^{2+}$ exchanger, generating abnormal depolarizing oscillations known as Early Afterdepolarizations (EADs) during Phase 2 or Phase 3.
• R-on-T Triggering: If an EAD reaches threshold potential, it generates an ectopic ventricular beat during the vulnerable repolarization window (R-on-T phenomenon), initiating Torsades de Pointes (TdP)—a polymorphic ventricular tachycardia characterized by QRS complexes that continuously twist their polarity around the isoelectric line at rates of 160 to 250 bpm.

IKr Channel Blockade ──> Prolonged Phase 3 Repolarization (Long QTc > 500 ms)
       │
       └──> L-type Ca2+ Influx Reactivation ──> Early Afterdepolarizations (EADs)
                   │
                   └──> R-on-T Ectopic Trigger ──> Polymorphic Torsades de Pointes

2. High-Risk Drug Culprits & Clinical Triggers

• Cardiovascular Culprits: Sotalol, dofetilide, ibutilide, quinidine, procainamide, and dronedarone. (Amiodarone markedly prolongs the QT interval but has a paradoxically low incidence of TdP [< 1%] because it simultaneously inhibits L-type calcium channels and beta-receptors, suppressing transmural dispersion of repolarization).
• Non-Cardiovascular Culprits: Antipsychotics (haloperidol, quetiapine, ziprasidone), antidepressants (citalopram, escitalopram), antibiotics (macrolides: azithromycin, clarithromycin; fluoroquinolones: levofloxacin, moxifloxacin), antifungals (fluconazole), and antiemetics (ondansetron).
• Critical Risk Threshold: Corrected QT interval (QTc > 500 ms via Bazett's or Fridericia's formula) or an increase in QTc of > 60 ms from baseline places the patient at imminent risk for degeneration into TdP.
• Predisposing Triggers: Severe hypokalemia ($K^+ < 4.0\text{ mEq/L}$), hypomagnesemia ($Mg^{2+} < 2.0\text{ mg/dL}$), profound bradycardia (rates < 50 bpm lengthen ventricular action potential duration and amplify EAD generation), female sex, acute myocardial ischemia, and baseline left ventricular systolic dysfunction.

3. Emergency Management Protocol for Torsades de Pointes

1. Stop Culprit Agents: Immediately discontinue all QT-prolonging drugs and correct any aggravating electrolyte disturbances.
2. Hemodynamically Unstable TdP (Pulseless or Severe Hypotension):
   • Initiate immediate unsynchronized electrical defibrillation (200 J biphasic). Synchronized cardioversion cannot accurately track polymorphic, undulating QRS peaks and will fail to discharge or discharge inappropriately on a T wave.
3. Hemodynamically Stable / Recurrent TdP:
   • First-Line Pharmacotherapy: Intravenous Magnesium Sulfate: Administer 1 to 2 grams IV diluted in 50 to 100 mL D5W infused over 1 to 2 minutes. If TdP persists or recurs, repeat the bolus in 5 to 15 minutes, followed by a continuous infusion of 0.5 to 1.0 g/hr. Magnesium acts as an antagonist to L-type calcium channels, suppressing EADs and terminating TdP even if baseline serum magnesium is entirely normal.
   • Accelerated Cardiac Pacing (Overdrive Pacing): Bradycardia directly precipitates pause-dependent TdP. Initiate temporary transvenous atrial or ventricular overdrive pacing at a rate of 90 to 110 bpm. Pacing shortens the ventricular action potential duration, shortens the QT interval, and suppresses pause-dependent EAD triggers.
   • Isoproterenol Infusion: In the absence of temporary pacing, an intravenous infusion of isoproterenol (a pure beta-agonist, titrated to maintain HR > 90–100 bpm) can be utilized to shorten the QTc. Contraindications: Strictly contraindicated in congenital long QT syndrome, acute coronary syndrome, or severe baseline myocardial ischemia.
   • Aggressive Potassium Repletion: Administer IV potassium chloride to achieve a high-normal serum potassium target of 4.5 to 5.0 mEq/L, which maximizes potassium channel conductance and accelerates myocardial repolarization.